Furthermore, the synergistic combination of MMWs with α-PD-L1 achieved high tumor suppression rates (up to 90%) and durable immune memory compared to either modality alone, effectively overcoming the primary limitations of immune checkpoint inhibitor monotherapy (e.g., poor response in “cold tumors” and acquired resistance). This evidence concerns the gene CD274 and neoplasm.